Portfoliotracker

Philogen S.p.A.

PHIL.MI · MILAN · Healthcare Biotechnology 100/100 A

20,95 €
▲ +0,10 (+0,48 %)
Trading delayed by 15 min
Price as of 17. 11. 11:27, fetched 17. 11. 11:43
Next earnings–
Ex-dividend–
Analysts–
50 / 200 day average– / –

Price

Portfoliotracker score100 / 100 Market cap840 mil. € P/E3,7 Forward P/E-83,6 P/S2,7 P/B2,5 EV/EBITDA2,0 Dividend yield3,36 % FCF yield31,22 % EPS5,58 € Net margin71,4 % Return on equity98,4 % Beta0,00 Debt / equity0,03
52-week range 19,56 to 26,00
3-month average volume0,0 M

Finance

Where the revenue goes

Loading the income statement flow…

Fundamentals

Loading key figures…

Insiders, analysts and people

All trades and changes

Loading insiders, analysts and opinions…

Co se právě děje

AI souhrn
Objednat AI souhrn, co se u firmy právě děje Vytvoří se jednou na pozadí a pak ho uvidí všichni. Ve verzi Free 3 objednávky měsíčně.

About the company

Philogen S.p.A., a biotechnology company, engages in the research and development of drugs for oncology and chronic inflammatory diseases in Italy, Switzerland, the United States, and the European Union. The company develops Nidlegy which is in Phase III clinical trial for the treatment of advanced melanoma and Phase II clinical trial for the treatment of basal cell carcinoma and cutaneous squamous cell carcinoma; Fibromun which is in Phase III clinical trial for the treatment of soft-tissue sarcoma and Phase II clinical trial for the treatment of glioblastoma; Darleukin which is in Phase II clinical trial for the treatment of non-small cell lung cancer; Dekavil which is in Phase II clinical trial for the treatment of chronic inflammatory disorders; and Dodekin which is in Phase I clinical trial for the treatment of various solid tumors. It is also involved in the development of small molecule products, including OncoFAP which is in Phase I clinical trial for the treatment of solid tumors; OncoACP3 which is in Phase I clinical trial for the treatment of prostate cancer; and OncoCAIX which is in Phase 1 trial for the treatment of renal cell carcinoma and other hypoxic tumors. The company was founded in 1996 and is headquartered in Sovicille, Italy.

Employees
230
Country
Italy
Data since
3. 3. 2021

Explore further

Similar companies GVS.MIPHN.MILUVE.MIICOS.MIIOT.MI

Intraday chart

Your own portfolio, properties and finances in one place.

The account is free with no time limit. Only you see your data; nobody adds it up with others.

This is saved to your account. You can keep browsing, calculating and comparing without signing in.

Welcome back

Sign in and pick up where you left off.

or continue with

No account yet? Create a free account